GOSS NASDAQ
Gossamer Bio, Inc.
1W: -23.6%
1M: +5941.7%
3M: +5948.5%
YTD: +272.6%
1Y: +245.0%
3Y: +952.0%
5Y: +4.1%
$10.73
-0.66 (-5.81%)
Weekly Expected Move ±3863.6%
$-818
$-404
$11
$425
$840
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$65.6M
52W Range9.104-309.6
Volume472,055
Avg Volume23,219,683
Beta2.00
Dividend—
Analyst Ratings
Company Info
CEOFaheem Hasnain
Employees162
SectorHealthcare
IndustryBiotechnology
IPO Date2019-02-08
Websitegossamerbio.com
3115 Merryfield Row
San Diego, CA 92121
US
San Diego, CA 92121
US
858 684 1300
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Latest News
BlackRock Inc. Purchases New Shares in Gossamer Bio, Inc. $GOSS
Corient Private Wealth LP Takes Position in Gossamer Bio, Inc. $GOSS
Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Christian Waage | A-Award | 2,900,026 | $0.17 | 2026-08-24 |
| Peterson Caryn | A-Award | 5,800,051 | $0.17 | 2026-08-24 |
| Smith Robert Paul JR | A-Award | 5,800,051 | $0.17 | 2026-08-24 |
| Giraudo Bryan | A-Award | 5,800,051 | $0.17 | 2026-08-24 |
| Hasnain Faheem | A-Award | 5,800,051 | $0.17 | 2026-08-24 |